Replies to post #151815 on Biotech Values

[genisi]

BMRN

Well, they were smart to go with the 6MWD. The bone growth can be shown in a post marketing trial. Indeed it's more than a skeletal disease, damage to many organs (heart, eyes, ears, lungs, GI) and no doubt that the sooner you start ERT to restore deficiency in the enzyme is better and treatment is needed for lifetime.